Low platelet count is potentially the most important contributor to severe bleeding in patients newly diagnosed with acute promyelocytic leukemia

被引:18
作者
Song, Yu-hua [1 ,2 ]
Peng, Peng [3 ]
Qiao, Chun [1 ]
Zhang, Run [1 ]
Li, Jian-yong [1 ]
Lu, Hua [1 ]
机构
[1] Nanjing Med Univ, Dept Hematol, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China
[2] Second Hosp Nanjing, Dept Hematol, Nanjing, Jiangsu, Peoples R China
[3] Second Hosp Nanjing, Dept Oncol, Nanjing, Jiangsu, Peoples R China
关键词
acute promyelocytic leukemia; all-trans retinoic acid; arsenic trioxide; coagulation; hemorrhage; FLT3 MUTATION STATUS; TRANS-RETINOIC ACID; PROGNOSTIC-FACTORS; INDUCTION THERAPY; ARSENIC TRIOXIDE; EARLY DEATH; RISK; CONSOLIDATION; COAGULOPATHY;
D O I
10.2147/OTT.S144438
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The objective of the current study was to provide more appropriate therapeutic strategies for reducing severe hemorrhaging by assessing the recovery of abnormal coagulation indexes in patients with acute promyelocytic leukemia (APL) during induction therapy. Retrospective analyses of 112 patients newly diagnosed with APL were performed during initial treatment. In our study, the early death rate was 5.36%. Hemorrhage was the leading cause of death during the induction period (4/6). The values of white blood cell count, lactate dehydrogenase, prothrombin time (PT), fibrinogen (Fbg), hemoglobin, and bone marrow leukemic promyelocytes were significantly different in the high-risk group compared to the low/intermediate-risk groups. There were significant differences in the white blood cell count, bone marrow leukemic promyelocytes, platelet (PLT) count, and the levels of lactate dehydrogenase, d-dimer, PT, and Fbg, as well as in FLT3-ITD mutations between patients with major bleeding and those with minor bleeding. Hemostatic variables significantly improved over time during induction therapy. The recovery times of the PLT, PT, and Fbg values were significantly slower in patients with major bleeding than in those with minor bleeding. Specifically, the PLT level in patients with major bleeding was not similar to that in the minor bleeding group until after 4 weeks of treatment. Hemorrhages were the most common cause of induction death in this study. High-risk patients were more prone to serious clinical bleeding symptoms. Patients with major bleeding had more rapid proliferation characteristics and an increased incidence of FLT3-ITD mutations compared to patients with minor bleeding. Hemostatic variables recovered significantly more slowly in patients with major bleeding than in those with minor bleeding. Active induction therapy and blood product infusion are effective in preventing severe bleeding. Our results suggested that low PLT count might be the leading cause of fatal bleeding in patients newly diagnosed with APL.
引用
收藏
页码:4917 / 4924
页数:8
相关论文
共 26 条
[1]   Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience [J].
Ades, Lionel ;
Guerci, Agnes ;
Raffoux, Emmanuel ;
Sanz, Miguel ;
Chevallier, Patrice ;
Lapusan, Simona ;
Recher, Christian ;
Thomas, Xavier ;
Rayon, Consuelo ;
Castaigne, Sylvie ;
Tournilhac, Olivier ;
de Botton, Stephane ;
Ifrah, Norbert ;
Cahn, Jean-Yves ;
Solary, Eric ;
Gardin, Claude ;
Fegeux, Nathalie ;
Bordessoule, Dominique ;
Ferrant, Augustin ;
Meyer-Monard, Sandrine ;
Vey, Norbert ;
Dombret, Herve ;
Degos, Laurent ;
Chevret, Sylvie ;
Fenaux, Pierre .
BLOOD, 2010, 115 (09) :1690-1696
[2]   AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance [J].
Avvisati, Giuseppe ;
Lo-Coco, Francesco ;
Paoloni, Francesca Paola ;
Petti, Maria Concetta ;
Diverio, Daniela ;
Vignetti, Marco ;
Latagliata, Roberto ;
Specchia, Giorgina ;
Baccarani, Michele ;
Di Bona, Eros ;
Fioritoni, Giuseppe ;
Marmont, Filippo ;
Rambaldi, Alessandro ;
Di Raimondo, Francesco ;
Kropp, Maria Grazia ;
Pizzolo, Giovanni ;
Pogliani, Enrico M. ;
Rossi, Giuseppe ;
Cantore, Nicola ;
Nobile, Francesco ;
Gabbas, Attilio ;
Ferrara, Felicetto ;
Fazi, Paola ;
Amadori, Sergio ;
Mandelli, Franco .
BLOOD, 2011, 117 (18) :4716-4725
[3]   Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia [J].
Candoni, A ;
Damiani, D ;
Michelutti, A ;
Masolini, P ;
Michieli, M ;
Michelutti, T ;
Geromin, A ;
Fanin, R .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (01) :1-8
[4]   Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia - a single center experience in 34 patients [J].
Dally, N ;
Hoffman, R ;
Haddad, N ;
Sarig, G ;
Rowe, JM ;
Brenner, B .
THROMBOSIS RESEARCH, 2005, 116 (02) :109-114
[5]   Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin [J].
de la Serna, Javier ;
Montesinos, Pau ;
Vellenga, Edo ;
Rayon, Chelo ;
Parody, Ricardo ;
Leon, Angel ;
Esteve, Jordi ;
Bergua, Juan M. ;
Milone, Gustavo ;
Deben, Guillermo ;
Rivas, Concha ;
Gonzalez, Marcos ;
Tormo, Mar ;
Diaz-Mediavilla, Joaquin ;
Gonzalez, Jose D. ;
Negri, Silvia ;
Amutio, Elena ;
Brunet, Salut ;
Lowenberg, Bob ;
Sanz, Miguel A. .
BLOOD, 2008, 111 (07) :3395-3402
[6]   Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia [J].
Estey, E ;
Garcia-Manero, G ;
Ferrajoli, A ;
Faderl, S ;
Verstovsek, S ;
Jones, D ;
Kantarjian, H .
BLOOD, 2006, 107 (09) :3469-3473
[7]   Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia [J].
Falanga, A ;
Rickles, FR .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2003, 16 (03) :463-482
[8]   Hypercoagulability and tissue factor gene upregulation in hematologic malignancies [J].
Falanga, Anna ;
Barbui, Tiziano ;
Rickles, Frederick R. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2008, 34 (02) :204-210
[9]   Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia [J].
Gale, RE ;
Hills, R ;
Pizzey, AR ;
Kottaridis, PD ;
Swirsky, D ;
Gilkes, AF ;
Nugent, E ;
Mills, KI ;
Wheatley, K ;
Solomon, E ;
Burnett, AK ;
Linch, DC ;
Grimwade, D .
BLOOD, 2005, 106 (12) :3768-3776
[10]   Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia [J].
Hu, Jiong ;
Liu, Yuan-Fang ;
Wu, Chuan-Feng ;
Xu, Fang ;
Shen, Zhi-Xiang ;
Zhu, Yong-Mei ;
Li, Jun-Min ;
Tang, Wei ;
Zhao, Wei-Li ;
Wu, Wen ;
Sun, Hui-Ping ;
Chen, Qiu-Sheng ;
Chen, Bing ;
Zhou, Guang-Biao ;
Zelent, Arthur ;
Waxman, Samuel ;
Wang, Zhen-Yi ;
Chen, Sai-Juan ;
Chen, Zhu .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (09) :3342-3347